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beneficial synergistic effects upon the blood pressure as well as the
vasculature.
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Statins reduce cardiovascular morbidity and mortality. These beneficial
effects are not fully explained by their lipid-lowering action. As such, we
investigated the impact of a new statin, rosuvastatin, on endothelial
function, the key event in early atherogenesis, in an experimental model
of normocholesterolemic hypertension.
Hypertension was induced in Wistar-Kyoto rats by inhibition of 11-
hydroxysteroid dehydrogenase type 2 (11-HSD2) with Glycyrrhizic
acid (GA). 11-HSD2 provides mineralocorticoid receptor specificity for
aldosterone by metabolising glucocorticoids to their receptor inactive
11-dehydro derivatives. GA was added to the drinking water (3 g/L) for
21 days. From days 8 to 21 rosuvastatin (20 mg/kg/d) or placebo were
added to chow. Endothelium-dependent and -independent relaxation of
isolated aortic rings to acetylcholine (ACh, 10-10-10-5 mol/L) and sodium
nitroprusside (SNP, 10-10-10-5 mol/L) was measured. In addition, vascu-
lar reactivity to endothelin-1 (ET-1; 10-10-10-7 mol/L) was investigated.
ETA and ETB receptor mRNA expression was determined by RT-PCR
and RhoA activity by a pull-down assay. Systolic blood pressure in-
creased in rats treated with GA (175 vs 153 mmHg in controls; p0.01).
Endothelium-dependent relaxations to acetylcholine were blunted after
GA treatment (p0.005 vs control), while the responses to SNP re-
mained unchanged. Rosuvastatin normalized NO-mediated endothelium-
dependent relaxation in hypertensive animals (p0.01 vs placebo),
although blood pressure and cholesterol levels were not affected by the
statin. Vascular reactivity to ET-1 was increased by GA (p0.01 vs
control), but not affected by rosuvastatin. ETB receptor mRNA decreased
in the GA group (p0.05 vs control) and was upregulated by rosuvastatin
(p0.005; GArosuvastatin vs GA), whereas ETA receptor mRNA
upregulation in the GA group (p0.01 vs control) was partially pre-
vented by the statin. In addition, GA increased Rho-GTP binding
(p0.05 vs control) which was prevented in both groups by rosuvastatin
treatment (p0.01 controlrosuvastatin vs control and
GArosuvastatin vs GA).
These data for the first time show that HMG-CoA inhibition improves
endothelial dysfunction in normocholesterolemic mineralocorticoid hy-
pertension without affecting blood pressure or cholesterol levels by
correction of a stimulated endothelin system.
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PLASMA IMMUNOREACTIVE ENDOTHELIN-1
LEVELS IN HYPERTENSIVE RATS AND HUMAN
SUBJECTS
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Switzerland.
Endothelin-1 (ET-1) is an endothelium-derived potent vasoconstrictor
peptide of 21 amino acids. To establish reference values in different
forms and models of hypertension and in human subjects an assay for
plasma ET-1 was optimized. Immunoreactive (ir-) ET-1 is extracted by
acetone from 1 ml plasma and subjected to a sensitive sandwich type
enzyme linked immunosorbent assay. The detection limit for plasma
ET-1 (3 SD above zero readings) is 0.05 fmol/ml. Mean recoveries of the
1, 2, 5, 10 fmol of ET-1 added to 1 ml plasma (n  5, each) were 66, 75,
85 and 92 % respectively. The within-assay coefficients of variation were
12, 5, 3, 3 and 0.5 % for plasma ET-1 concentrations of 0.84, 1.5, 2.3, 5.2
and 9.9 fmol/ml respectively. Between-assay coefficients of variation for
two human control plasmas containing 1.0 fmol/ml (n  8) and 1.2
fmol/ml ET-1 (n  7) were 8% and 10% respectively. Assay accuracy
was demonstrated by the consistent recoveries of added ET-1 and by the
linearity of ir-ET-1 concentrations measured in serially diluted plasma
extracts (r  0.99). No ir-ET-1 was detected when albumin buffer was
extracted instead of plasma (buffer blank). Using this method, we found
increased ir-ET-1 levels in plasma of three experimental rat models of
hypertension. (i) Plasma ir-ET-1 concentrations were significantly higher
in stroke-prone spontaneously hypertensive rats (SP-SHR) than in nor-
motensive Wistar rats. (ii) DOCA-salt hypertensive rats exhibited 4 times
higher ir-ET-1 levels than sham operated control rats. (iii) One kidney-
one clip (1K-1C) hypertensive rats showed moderately increased ir-ET-1
levels compared to sham operated controls. In contrast, the ir-ET-1 levels
in plasma of SHR were half that of normotensive Wistar rats. In two
kidney-one clip (2K-1C) Goldblatt hypertensive rats, the plasma ir-ET-1
concentrations were not different from sham-operated control rats. The
plasma ir-ET-1 concentrations of 37 healthy human subjects were 0.85
0.26 fmol/ml (mean  SD). We conclude that the present assay reliably
measures plasma immunoreactive ET-1 levels in rats and in human
subjects. Normal plasma ET-1 concentrations in humans and conscious
rats are in the low picomolar range.
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Adrenomedullin (AM) exerts a wide variety of biological effects, includ-
ing potent vasorelaxation. Its receptors were recently shown to be het-
erodimers comprised of a novel accessory protein, the receptor activity-
modifying protein (RAMP), and the calcitonin receptor-like receptor
(CRLR). When CRLR is co-transfected with RAMP2 or -3, the two
proteins are transported together to the plasma membrane where they
function as an AM-specific receptor. Recently, we have shown that seven
amino acids of human (h)RAMP2 (86-92) and hRAMP3 (59-65) are
essential for high-affinity agonist binding to hAM receptors. Interest-
ingly, both seven-residue segments are located between three conserved
residues (Trp, Cys and Tyr) and the three ones are common to humans,
rats and mice. In this study, we examined whether seven-residue seg-
ments situated between three residues conserved in both rat (r)RAMP2
and rRAMP3 (amino acids 93-99 and 58-64, respectively) are key
determinants of agonist binding to rAM receptors, and then tested
whether their deletion mutants can act as dominant negative RAMPs.
Control
Ang II
(n  8)
Ang II-AML
(n  7)
SBP (mmHg) 135  2 175  3* 132  6
Body Weight (g) 288  10 261  11** 261  10**
Ao weight (mg/cm) 13.2  0.3 16.9  1.3* 13.4  0.4
O2 (cpm/mg/min) 608  159 1005  140* 595  62
ONOO (cpm/mg/min) 782  115 1875  295* 1142  134
Emax (% of NE contraction) 105  4 86  3* 102  3
ED50 ( Log M) 8.0  0.27 6.6  0.19* 7.6  0.18
* P  0.05 vs Control and Ang II—AML; ** P  0.05 vs Control
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